Re-induction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL): Phase II Results from Children’s Oncology Group (COG) Study ADVL04P2

BACKGROUND: Given the success of immunotherapeutic approaches in hematologic malignancies, the COG designed a phase I/II study to determine whether the addition of epratuzumab (anti-CD22) to an established chemotherapy platform improves rates of second remission (CR2) in pediatric patients with B-ly...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Pediatr Blood Cancer
Autori principali: Raetz, Elizabeth A., Cairo, Mitchell S., Borowitz, Michael J., Lu, Xiaomin, Devidas, Meenakshi, Reid, Joel M., Goldenberg, David M., Wegener, William A., Zeng, Hui, Whitlock, James A., Adamson, Peter C., Hunger, Stephen P., Carroll, William L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701208/
https://ncbi.nlm.nih.gov/pubmed/25732247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25454
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi